How big is Cytek Biosciences, Inc.?

As of Jun 18, Cytek Biosciences, Inc. has a market capitalization of 404.04 million, with net sales of 197.06 million and a net profit of -11.25 million over the latest four quarters. Shareholder's funds are reported at 395.74 million, and total assets amount to 502.08 million.

As of Jun 18, Cytek Biosciences, Inc. has a market capitalization of 404.04 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 197.06 million, while the sum of net profit for the same period is -11.25 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 395.74 million, and total assets amount to 502.08 million.

What does Cytek Biosciences, Inc. do?

Cytek Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $41 million and a net loss of $11 million as of March 2025. The company has a market cap of $404.04 million and does not pay dividends.

Overview: <BR>Cytek Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 41 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 404.04 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.65 <BR>Return on Equity: -5.40% <BR>Price to Book: 1.06<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Cytek Biosciences, Inc.?

Is Cytek Biosciences, Inc. overvalued or undervalued?

As of May 9, 2023, Cytek Biosciences, Inc. has shifted from an attractive to a risky valuation grade due to overvaluation indicated by poor financial metrics and significant underperformance relative to the S&P 500.

As of 9 May 2023, the valuation grade for Cytek Biosciences, Inc. moved from attractive to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.15, an EV to Sales ratio of 0.96, and a troubling ROCE of -20.58%. In comparison to peers, Cytek's EV to EBITDA ratio of -11.49 is significantly worse than Paragon 28, Inc. at -52.8268 and SI-BONE, Inc. at -25.8938, both of which also carry a risky valuation grade.<BR><BR>The stock has underperformed relative to the S&P 500, with a year-to-date return of -36.98% compared to the index's positive return of 12.22%. This underperformance reinforces the view that Cytek Biosciences, Inc. is currently overvalued in the market.

Is Cytek Biosciences, Inc. technically bullish or bearish?

As of October 31, 2025, Cytek Biosciences, Inc. is in a mildly bearish trend, indicated by daily moving averages and monthly KST, despite some bullish signals from weekly MACD and Dow Theory, and has significantly underperformed the S&P 500 with a year-to-date return of -39.29%.

As of 31 October 2025, the technical trend for Cytek Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, while weekly and monthly MACD and Dow Theory show mildly bullish signals. However, the overall bearish sentiment is reinforced by the KST being bearish on a monthly basis and Bollinger Bands indicating a mildly bearish trend monthly. The stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -39.29% compared to the S&P 500's 16.30%.